Wednesday, May 08, 2024 Congratulations to the IND241 trial team at Princess Margaret Cancer Centre who were awarded the CCTG IND Team Award at the Annual Spring Meeting this past weekend. The team members include, David Cescon (QI), Julia Wang, Soha Ahrari, Irene Li, Simi Malhotra, Lindsay Muyot, Helia Purnaghshband, Carolina Sanabria Salas, Maria Ye, Divyalakshmi Babu, Jennifer Bornstein, Christine Cater, Julia D'Souza, Shirley Ho, Ansu Jomy Jose, Sul Hee Kim, Irum Mahmood, Alexis Maneja, Karla Moreira, Sam (sang pil) Park, and Rosa Pezzulli“We're very excited to receive the CCTG Investigational New Drug (IND) Team Award! This award is a reflection of our site’s successful collaborative efforts with the CCTG IND central office team on the innovative IND241 breast cancer trial. It's truly an honor to see our hard work recognized. We're eager to keep pushing the boundaries of breast cancer research and are grateful to everyone involved for their support and dedication.”The IND241 is a liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer. The purpose of the pre-study screening is to test for biomarkers done using a sample of your blood. Patients are sorted into one of the sub-studies, depending on eligibility and availability. Each sub-study will be looking at what effects a new drug has on the patients and their breast cancer, as well as any side effects of the treatment.
